新型糖皮质激素制剂用于类风湿关节炎:现状与发展  

New preparations and delivery systems of glucocorticoids for the treatment of rheumatoid arthritis:state of the art and future directions

作　　者：谢文慧 张卓莉[1] XIE Wen-hui;ZHANG Zhuo-li(Department of Rheumatology and Clinical Immunology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院风湿免疫科,北京100034

出　　处：《中华临床免疫和变态反应杂志》2019年第1期86-90,共5页Chinese Journal of Allergy & Clinical Immunology

基　　金：国家自然科学基金项目(81501400,81771740);国家科技支撑项目(2010CB529100);首都卫生发展科技专项基金项目(2011-4021-03);北京大学临床研究项目(PUCRP201305)。

摘　　要：类风湿关节炎(rheumatoidarthritis,RA)是以关节滑膜慢性炎症为特征的系统性自身免疫性疾病。糖皮质激素因其强抗炎、起效快、价廉等特点,在RA治疗中发挥重要“桥梁”作用。由于传统糖皮质激素的不良反应相对较多,一定程度上限制了在RA的临床应用。新型糖皮质激素制剂的研究探索旨在保留激素优点的同时,减少其相关的不良反应,具备重要的潜在临床价值。本文综述新型糖皮质激素制剂在RA治疗的研究现状,旨在为国内风湿免疫科医师提供最新研究进展的信息。Rheumatoid arthritis(RA)is a chronic inflammatory joint disease,which can cause bone damage and disability.Glucocorticoids are highly regarded as“bridge”therapy in the management of RA for long time because of its potent anti-inflammatory effects,low cost,and accessibility.However,a range of adverse reactions induced by glucocorticoids have largely limited its application in daily practice.In recent years,several new preparations and drug delivery systems are being developed in order to improve risk-benefit ratio.In this review,we provide a detailed overview of the progress of these novel glucocorticoids-based therapies in the management of RA.

关 键 词：类风湿关节炎 糖皮质激素 新型制剂 泼尼松缓释片 脂质体糖皮质激素 选择性糖皮质激素受体激动剂 

分 类 号：R59[医药卫生—内科学]